摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-hydrazinocarbonylmethyl-5-methyl-hexanoic acid | 1159446-16-8

中文名称
——
中文别名
——
英文名称
3-hydrazinocarbonylmethyl-5-methyl-hexanoic acid
英文别名
3-(2-hydrazinyl-2-oxoethyl)-5-methylhexanoic acid
3-hydrazinocarbonylmethyl-5-methyl-hexanoic acid化学式
CAS
1159446-16-8
化学式
C9H18N2O3
mdl
——
分子量
202.254
InChiKey
PIQKXPOEPQFHOJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.9
  • 重原子数:
    14
  • 可旋转键数:
    6
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.78
  • 拓扑面积:
    92.4
  • 氢给体数:
    3
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    3-hydrazinocarbonylmethyl-5-methyl-hexanoic acid盐酸 、 sodium nitrite 作用下, 以 甲苯 为溶剂, 反应 0.33h, 生成
    参考文献:
    名称:
    A process for the preparation of (S)(+)-3-(aminomethyl)-5-methylhexanoic acid
    摘要:
    一种制备式(I)化合物的方法,包括:a)将式(II)化合物与肼反应,得到式(III)化合物;b)通过在溶剂式R1-OH中发生亚硝基/异氰酸酯的重排反应,将式(III)化合物转化为式(IV)化合物;c)对式(IV)化合物进行对映体富集,得到式(V)化合物的对映体(S);d)对式(V)化合物进行水解。其中,R1的定义如本文所述。
    公开号:
    EP2067768A1
  • 作为产物:
    描述:
    3-异丁基戊二酸酐sodium hydroxide 作用下, 以 为溶剂, 反应 3.0h, 生成 3-hydrazinocarbonylmethyl-5-methyl-hexanoic acid
    参考文献:
    名称:
    A process for the preparation of (S)(+)-3-(aminomethyl)-5-methylhexanoic acid
    摘要:
    一种制备式(I)化合物的方法,包括:a)将式(II)化合物与肼反应,得到式(III)化合物;b)通过在溶剂式R1-OH中发生亚硝基/异氰酸酯的重排反应,将式(III)化合物转化为式(IV)化合物;c)对式(IV)化合物进行对映体富集,得到式(V)化合物的对映体(S);d)对式(V)化合物进行水解。其中,R1的定义如本文所述。
    公开号:
    EP2067768A1
点击查看最新优质反应信息

文献信息

  • PROCESS FOR THE PREPARATION OF PREGABALIN
    申请人:HIKAL LIMITED
    公开号:US20150344919A1
    公开(公告)日:2015-12-03
    The present invention provides an improved process for the preparation of a compound of formula (I), which comprises the steps of: formula (I), (a) reacting isovaleraldehyde of formula (II) and alkyl cyanoacetate of formula (III) optionally in presence of salts of weak acid and weak base or weak base in a suitable solvent to get 2-cyano-5-methyl-hex-2-enoic acid alkyl ester of formula (IV); (b) reacting 2-cyano-5-methyl-hex-2-enoic acid alkyl ester of formula (IV) with a suitable cyanide source in water or in an organic solvent or mixture thereof to get 2-isobutylsuccinonitrile of formula (V); (c) obtaining optionally 2-isobutylsuccinonitrile of formula (V) by reacting isovaleraldehyde of formula (II) and alkyl cyanoacetate of formula (III) in presence of suitable cyanide source in water or in an organic solvent or mixture thereof in single step; (d) converting 2-isobutylsuccinonitrile of formula pa (V) to racemic 3-cyano-5-methyl-hexanoic acid or salt thereof of formula (VI) with a genetically modified nitrilase enzyme (Nit pt 9N_56_2) in water or optionally with an organic co-solvent at appropriate pH and temperature; (e) converting racemic 3-cyano-5-methyl-hexanoic acid or salt thereof of formula (VI) to racemic alkyl 3-cyano-5-methyl-hexanoate of formula (VII) by treatment with alcohol (R3OH) and acidic catalyst or alkyl halide (R3X) in presence of a base in a suitable solvent or a mixture of solvents thereof; (f) obtaining (S)-alkyl 3-cyano-5-methyl-hexanoate of formula (VIII) and (R)-3-cyano-5-methyl-hexanoic acid or salt thereof of formula (X) by enzymatic enantioselective hydrolysis in water or organic solvent or a mixture thereof from racemic alkyl 3-cyano-5-methyl-hexanoate of formula (VII); (g) obtaining optionally the compound of formula (VII) by racemizing unwanted (R)-3-cyano-5-methyl-hexanoic acid or salt thereof of formula (X) or substantially enriched (R)-3-cyano-5-methyl-hexanoic acid salt thereof of formula (X) in presence of a base in organic solvent or a mixture thereof; (h) converting (S)-alkyl 3-cyano-5-methyl-hexanoate of formula (VIII) to pregabalin of formula (I) by hydrolyzing ester group with suitable alkali or alkaline earth metal base followed by hydrogenation optionally in one pot in a solvent selected from water or other organic solvents or a mixture thereof in presence of a suitable hydrogenation catalyst.
    本发明提供了一种改进的制备化合物(I)的方法,包括以下步骤:式(I),(a)在适当溶剂中,将式(II)异戊醛和式(III)烷基氰乙酸酯在弱酸和弱碱盐或弱碱的存在下反应,得到式(IV)的2-氰基-5-甲基-己-2-烯酸烷基酯;(b)将式(IV)的2-氰基-5-甲基-己-2-烯酸烷基酯与适当的氰化物源在水中或有机溶剂中或二者的混合物中反应,得到式(V)的2-异丁基琥珀酰腈;(c)通过在水中或有机溶剂中或二者的混合物中的单步反应,将式(II)异戊醛和式(III)烷基氰乙酸酯在适当的氰化物源的存在下反应,可选地获得式(V)的2-异丁基琥珀酰腈;(d)通过在水中或适当的pH和温度下,用一种基因改造的腈酶酶(Nit pt 9N_56_2)将式(V)的2-异丁基琥珀酰腈转化为外消旋3-氰基-5-甲基-己酸或其盐的式(VI);(e)通过在适当溶剂或其混合物中,在碱的存在下,用醇(R3OH)和酸性催化剂或烷基卤化物(R3X)处理,将式(VI)的外消旋3-氰基-5-甲基-己酸或其盐转化为式(VII)的外消旋烷基3-氰基-5-甲基-己酸酯;(f)通过在水或有机溶剂或其混合物中,通过酶选择性立体选择性水解,从式(VII)的外消旋烷基3-氰基-5-甲基-己酸酯获得(S)-烷基3-氰基-5-甲基-己酸酯的式(VIII)和(R)-3-氰基-5-甲基-己酸或其盐的式(X);(g)通过在有机溶剂或其混合物中,在碱的存在下,将不需要的(R)-3-氰基-5-甲基-己酸或其盐的式(X)或富集的(R)-3-氰基-5-甲基-己酸或其盐的式(X)外消旋化,可选地获得式(VII)的化合物;(h)通过在水或其他有机溶剂或其混合物中,在适当的氢化催化剂的存在下,将(S)-烷基3-氰基-5-甲基-己酸酯转化为式(I)的前列酸,首先用适当的碱或碱土金属碱水解酯基,然后在一个锅中进行氢化。
  • Process for the Preparation of (S)(+)-3-(Aminomethyl)-5-Methylhexanoic Acid
    申请人:Allegrini Pietro
    公开号:US20090143615A1
    公开(公告)日:2009-06-04
    A process for the preparation of a compound of formula (I), comprising: a) the reaction of a compound of formula (II) with hydrazine to obtain a compound of formula (III), b) the conversion of a compound of formula (III) by rearrangement via formation of nitrene/isocyanate, in a solvent of formula R 1 —OH, wherein R 1 is as herein defined, to obtain a compound of formula (IV); c) the enantiomeric enrichment of a compound of formula (IV) to obtain the enantiomer (S) of a compound of formula (V) d) the hydrolysis of a compound of formula (V).
    一种制备式(I)化合物的方法,包括:a)将式(II)化合物与肼反应,得到式(III)化合物;b)通过在式R1-OH的溶剂中发生亚硝基/异氰酸酯的重排反应,将式(III)化合物转化为式(IV)化合物;c)对式(IV)化合物进行对映体富集,得到式(V)化合物的对映体(S);d)对式(V)化合物进行水解。其中,R1如本文所定义。
  • Process for the preparation of pregabalin
    申请人:HIKAL LIMITED
    公开号:US10023885B2
    公开(公告)日:2018-07-17
    The present invention provides an improved process for the preparation of a compound of formula (I), which comprises the steps of: formula (I), (a) reacting isovaleraldehyde of formula (II) and alkyl cyanoacetate of formula (III) optionally in presence of salts of weak acid and weak base or weak base in a suitable solvent to get 2-cyano-5-methyl-hex-2-enoic acid alkyl ester of formula (IV); (b) reacting 2-cyano-5-methyl-hex-2-enoic acid alkyl ester of formula (IV) with a suitable cyanide source in water or in an organic solvent or mixture thereof to get 2-isobutylsuccinonitrile of formula (V); (c) obtaining optionally 2-isobutylsuccinonitrile of formula (V) by reacting isovaleraldehyde of formula (II) and alkyl cyanoacetate of formula (III) in presence of suitable cyanide source in water or in an organic solvent or mixture thereof in single step; (d) converting 2-isobutylsuccinonitrile of formula (V) to racemic 3-cyano-5-methyl-hexanoic acid or salt thereof of formula (VI) with a genetically modified nitrilase enzyme (Nit 9N_56_2) in water or optionally with an organic co-solvent at appropriate pH and temperature; (e) converting racemic 3-cyano-5-methyl-hexanoic acid or salt thereof of formula (VI) to racemic alkyl 3-cyano-5-methyl-hexanoate of formula (VII) by treatment with alcohol (R3OH) and acidic catalyst or alkyl halide (R3X) in presence of a base in a suitable solvent or a mixture of solvents thereof; (f) obtaining (S)-alkyl 3-cyano-5-methyl-hexanoate of formula (VIII) and (R)-3-cyano-5-methyl-hexanoic acid or salt thereof of formula (X) by enzymatic enantioselective hydrolysis in water or organic solvent or a mixture thereof from racemic alkyl 3-cyano-5-methyl-hexanoate of formula (VII); (g) obtaining optionally the compound of formula (VII) by racemizing unwanted (R)-3-cyano-5-methyl-hexanoic acid or salt thereof of formula (X) or substantially enriched (R)-3-cyano-5-methyl-hexanoic acid salt thereof of formula (X) in presence of a base in organic solvent or a mixture thereof; (h) converting (S)-alkyl 3-cyano-5-methyl-hexanoate of formula (VIII) to pregabalin of formula (I) by hydrolyzing ester group with suitable alkali or alkaline earth metal base followed by hydrogenation optionally in one pot in a solvent selected from water or other organic solvents or a mixture thereof in presence of a suitable hydrogenation catalyst.
    本发明提供了一种制备式(I)化合物的改进工艺,该工艺包括以下步骤:式(I),(a)使式(II)的异戊醛和式(III)的氰乙酸烷基酯(可选择在弱酸和弱碱或弱碱的盐存在下)在合适的溶剂中反应,得到式(IV)的2-氰基-5-甲基-己-2-烯酸烷基酯;(b) 将式(IV)的 2-氰基-5-甲基-己-2-烯酸烷基酯与合适的氰源在水或有机溶剂或其混合物中反应,得到式(V)的 2-异丁基琥珀腈;(c) 将式(II)的异戊醛和式(III)的氰乙酸烷基酯在水中或有机溶剂或其混合物中,在适 当氰化物源存在下进行反应,得到式(V)的 2-异丁基琥珀腈;(d) 在适当的 pH 值和温度下,用转基因硝化酶(Nit 9N_56_2)在水中或任选用有机 助溶剂中将式(V)的 2-异丁基琥珀腈转化为式(VI)的外消旋 3-氰基-5-甲基己酸或其盐;(e) 在适当溶剂或其混合物中,在碱存在下,用醇 (R3OH) 和酸性催化剂或烷基卤化物 (R3X) 处理,将式 (VI) 的外消旋 3-氰基-5-甲基己酸或其盐转化为式 (VII) 的外消旋 3-氰基-5-甲基己酸烷基酯;(f) 从式(VII)的外消旋 3-氰基-5-甲基己酸烷基酯在水或有机溶剂或其混合物中通过酶对映 选择性水解得到式(VIII)的(S)-3-氰基-5-甲基己酸烷基酯和式(X)的(R)-3-氰基-5-甲基己酸或其盐;(g) 在有机溶剂或其混合物中,在碱存在下,通过外消旋化不需要的(R)-3-氰基-5-甲基己酸或式(X)的其盐或基本富集的(R)-3-氰基-5-甲基己酸式(X)的其盐,得到可选的式(VII)化合物;(h) 将式(VIII)的(S)-3-氰基-5-甲基己酸烷基酯转化为式(I)的普瑞巴林,方法是先用适当的碱金属或碱土金属碱水解酯基,然后在适当的氢化催化剂存在下,任选在选自水或其他有机溶剂或其混合物的溶剂中一次氢化。
  • [EN] A PROCESS FOR THE PREPARATION OF PREGABALIN<br/>[FR] PROCÉDÉ DE PRÉPARATION DE PRÉGABALINE
    申请人:HIKAL LTD
    公开号:WO2014072785A2
    公开(公告)日:2014-05-15
    The present invention provides an improved process for the preparation of a compound of formula (I), which comprises the steps of: formula (I), (a) reacting isovaleraldehyde of formula (II) and alkyl cyanoacetate of formula (III) optionally in presence of salts of weak acid and weak base or weak base in a suitable solvent to get 2-cyano-5- methyl-hex-2-enoic acid alkyl ester of formula (IV); (b) reacting 2-cyano-5-methyl-hex-2-enoic acid alkyl ester of formula (IV) with a suitable cyanide source in water or in an organic solvent or mixture thereof to get 2-isobutylsuccinonitrile of formula (V); (c) obtaining optionally 2-isobutylsuccinonitrile of formula (V) by reacting isovaleraldehyde of formula (II) and alkyl cyanoacetate of formula (III) in presence of suitable cyanide source in water or in an organic solvent or mixture thereof in single step; (d) converting 2-isobutylsuccinonitrile of formula (V) to racemic 3-cyano-5-methyl-hexanoic acid or salt thereof of formula (VI) with a genetically modified nitrilase enzyme (Nit 9N_56_2) in water or optionally with an organic co-solvent at appropriate pH and temperature; (e) converting racemic 3-cyano-5-methyl-hexanoic acid or salt thereof of formula (VI) to racemic alkyl 3-cyano-5-methyl-hexanoate of formula (VII) by treatment with alcohol (R3OH) and acidic catalyst or alkyl halide (R3X) in presence of a base in a suitable solvent or a mixture of solvents thereof;.(f) obtaining (S)-alkyl 3 -cyano-5 -methyl -hexanoate of formula (VIII) and (R)-3-cyano-5-methyl- hexanoic acid or salt thereof of formula (X) by enzymatic enantioselective hydrolysis in water or organic solvent or a mixture thereof from racemic alkyl 3-cyano-5-methyl-hexanoate of formula (VII);.(g) obtaining optionally the compound of formula (VII) by racemizing unwanted (R)-3-cyano-5- methyl-hexanoic acid or salt thereof of formula (X) or substantially enriched (R)-3 -cyano-5 - methyl-hexanoic acid salt thereof of formula (X) in presence of a base in organic solvent or a mixture thereof; (h) converting (S)-alkyl 3-cyano-5-methyl-hexanoate of formula (VIII) to pregabalin of formula (I) by hydrolyzing ester group with suitable alkali or alkaline earth metal base followed by hydrogenation optionally in one pot in a solvent selected from water or other organic solvents or a mixture thereof in presence of a suitable hydrogenation catalyst.
  • A process for the preparation of (S)(+)-3-(aminomethyl)-5-methylhexanoic acid
    申请人:Dipharma Francis S.r.l.
    公开号:EP2067768A1
    公开(公告)日:2009-06-10
    A process for the preparation of a compound of formula (I), comprising: a) the reaction of a compound of formula (II) with hydrazine to obtain a compound of formula (III), b) the conversion of a compound of formula (III) by rearrangement via formation of nitrene/isocyanate, in a solvent of formula R1-OH, wherein R1 is as herein defined, to obtain a compound of formula (IV); c) the enantiomeric enrichment of a compound of formula (IV) to obtain the enantiomer (S) of a compound of formula (V) d) the hydrolysis of a compound of formula (V).
    一种制备式(I)化合物的方法,包括:a)将式(II)化合物与肼反应,得到式(III)化合物;b)通过在溶剂式R1-OH中发生亚硝基/异氰酸酯的重排反应,将式(III)化合物转化为式(IV)化合物;c)对式(IV)化合物进行对映体富集,得到式(V)化合物的对映体(S);d)对式(V)化合物进行水解。其中,R1的定义如本文所述。
查看更多